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Citalopram inhibits platelet 
function independently of SERT-
mediated 5-HT transport
Harvey G. Roweth1, Ruoling Yan1, Nader H. Bedwani1, Alisha Chauhan1, Nicole Fowler1,  
Alice H. Watson1, Jean-Daniel Malcor2, Stewart O. Sage1 & Gavin E. Jarvis  1
Citalopram prevents serotonin (5-HT) uptake into platelets by blocking the serotonin reuptake 
transporter (SERT). Although some clinical data suggest that selective serotonin reuptake inhibitors 
(SSRIs) may affect haemostasis and thrombosis, these poorly-characterised effects are not well 
understood mechanistically and useful in vitro data is limited. We sought to determine whether the 
inhibitory effects of citalopram on platelets are mediated via its pharmacological inhibition of 5-HT 
transport. We quantified the inhibitory potency of (RS)-, (R)- and (S)-citalopram on platelet function. If 
SERT blockade is the primary mechanism for citalopram-mediated platelet inhibition, these potencies 
should show quantitative congruence with inhibition of 5-HT uptake. Our data show that citalopram 
inhibits platelet aggregation, adhesion and thromboxane production with no difference in potency 
between (R)- and (S)-isomers. By contrast, citalopram had a eudysmic ratio of approximately 17 
(S > R) for SERT blockade. Furthermore, nanomolar concentrations of citalopram inhibited 5-HT 
uptake into platelets but had no effect on other platelet functions, which were inhibited by micromolar 
concentrations. Our data indicate that citalopram-induced inhibition of platelets in vitro is not 
mediated by blockade of 5-HT transport. This raises a new question for future investigation: by what 
mechanism(s) does citalopram inhibit platelets?
Citalopram is a selective serotonin reuptake inhibitor (SSRI) commonly used in the treatment of depression1. 
It inhibits the serotonin transporter (SERT), a member of the solute carrier family of transporters (SLC6A4), 
thereby preventing reuptake of serotonin (5-hydroxytryptamine, 5-HT) into nerve terminals and other cells, 
including platelets2. Most 5-HT in the body is synthesised and located in the gastrointestinal tract3. 5-HT released 
into the portal circulation is metabolised by the liver and transported by SERT into platelets, where it is stored in 
dense granules, resulting in low plasma concentrations of 5-HT4. Platelets are key mediators of both haemostasis 
and thrombosis, although the role played by 5-HT in these responses is thought to be limited. 5-HT is regarded 
as a weak platelet agonist, potentiating the activity of other agonists, such as ADP and thromboxane A2 (TxA2)5. 
Activated platelets release 5-HT, and this may contribute to thrombosis or haemostasis via 5-HT2A receptors on 
platelets or vascular smooth muscle6,7.
Clinical use of SSRIs for depression has been associated with a reduced risk of myocardial infarction8 and an 
increased risk of haemorrhage9–11. Such observations combined with SERT expression on platelets have led to 
suggestions that SSRIs could be used to manage thrombotic disease12 via a direct effect on platelets13–15. However, 
other studies have associated SSRI use with an increased risk of myocardial infarction16,17, suggesting a more 
complex picture18. Many ex vivo studies into the effect of SSRIs on platelet function have been performed. Some 
reported reduced aggregation19,20, and in some cases the effect varied depending on the agonist2.
Despite strong circumstantial links between SSRIs, platelets and cardiovascular disease, “few studies show 
direct effects in vitro of SSRIs on haemostasis”21. Among those that do, some report inhibitory effects12,22–24, some 
increased aggregation25, and others little effect26 of SSRIs on platelets.
Depletion of intra-platelet 5-HT stores following prolonged therapy is a mechanism whereby SSRIs could 
reduce thrombosis27. However, direct and rapid effects of SSRIs on platelets in vitro2,22,23 suggest there may be 
alternative mechanisms. Citalopram was reported to specifically inhibit collagen-induced aggregation, potentially 
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via a SERT-dependent mechanism22. However, the concentration of citalopram required suggested that its mech-
anism of action was not a direct consequence of SERT inhibition.
The objectives of this study were: (1) to characterise the inhibitory effect of citalopram on platelets; and (2) to 
determine whether citalopram inhibits platelets in a SERT-dependent manner. Citalopram is a 50:50 racemic (RS) 
mixture of isomers: (S)-citalopram is reported to be ~30-fold more potent than (R)-citalopram28. We used (RS)-, 
(R)- and (S)-citalopram and compared potencies for inhibition of 5-HT uptake with functional platelet inhibi-
tion. We conclude that citalopram does inhibit platelets in vitro, although not via inhibition of 5-HT transport. 
Consequently, alternative mechanisms are necessary to explain the effects of citalopram on platelets.
Results
Citalopram inhibits platelet aggregation. Preliminary experiments revealed that citalopram inhib-
ited platelet aggregation at concentrations above 10 µM. Subsequent experiments (using 7 blood donors) were 
designed to quantify the inhibitory potency of (RS)-, (R)- and (S)-citalopram on collagen- and U46619-induced 
aggregation. For each donor, full agonist concentration-response curves were obtained at 0, 20, 50 and 100 µM 
citalopram for collagen, and 0, 50, 100 and 200 µM citalopram for U46619. Collagen and U46619 experiments 
were conducted on separate occasions.
Figure 1a shows inhibition of collagen- and U46619-induced aggregation by (RS)-citalopram. Figure 1b 
shows the effect of (RS)-citalopram on the maximum extent of aggregation induced by a full range of colla-
gen or U46619 concentrations. Similar inhibition was observed for (R)- and (S)- citalopram. For each donor, 
responses to 1 µg mL−1 collagen or 0.2 µM U46619 (sub-maximal under control conditions, see Fig. 1b) were 
fitted to the 4-parameter logistic (4PL) model, with Max constrained to zero (Fig. 1c). Citalopram pIC50 values 
for both agonists in each donor were obtained and summary results are shown in Table 1. (U46619 data from one 
experimental day was excluded as the model failed to converge on a meaningful solution). 3-way ANOVA indi-
cated no difference in inhibitory potency between the citalopram isomers (P = 0.95). There was a small difference 
(0.125 ± 0.068) in citalopram pIC50 values between collagen and U46619 (P = 0.08).
Citalopram inhibits static platelet adhesion. The effect of (RS)-, (R)- and (S)-citalopram on the static 
adhesion of platelets to different adhesive ligands was determined. Full concentration-inhibition curves were 
constructed using 0, 10, 30, 50, 100, 200 and 300 µM citalopram for four adhesive ligands: (1) collagen; (2) 
collagen-related peptide (CRP), a selective ligand for the collagen receptor, glycoprotein VI (GPVI); (3) fibrin-
ogen, a ligand for integrin αIIbβ3; and (4) GFOGER, a selective ligand for the collagen receptor, integrin α2β129. 
Two negative controls were used: BSA controls for well blocking, and GPP controls for the (GPP)n sequences in 
GFOGER and for non-specific triple-helical interactions30 (Fig. 2). Owing to logistical constraints, all citalopram 
conditions could not be measured in a single experiment. Hence, in 7 donors (RS)-citalopram was tested, in 2 
donors (R) and (S) were tested, and in 2 donors (RS)-, (R)- and (S)-citalopram were tested.
Comparison with the negative controls suggests that citalopram fully inhibited static adhesion of platelets to 
the adhesive ligands. For each donor and ligand combination, citalopram-induced inhibition of adhesion was 
fitted to the 4PL model and pIC50 values obtained (Table 1). 3-way ANOVA indicated no difference in inhibitory 
potency between the citalopram isomers (P = 0.32).
Citalopram inhibits TxA2 synthesis by platelets. TxA2 synthesis was indirectly measured by quantify-
ing the generation of its stable metabolite TxB2 (N = 6). Washed platelets were pre-treated with a range of (RS)-, 
(R)- and (S)-citalopram concentrations (0, 5, 10, 20, 50, 100 and 200 µM), before stimulation under aggregometry 
conditions for 6 min with 1 µg mL−1 collagen. pIC50 values are shown in Table 1. All three citalopram preparations 
inhibited TxB2 generation at micromolar concentrations (Fig. 3). 2-way ANOVA indicated no difference in pIC50 
values between citalopram preparations (P = 0.60).
(Aggregometry data obtained from these experiments were independent replicates and reproduced results for 
inhibition of collagen-induced aggregation: pIC50(RS) = 4.43 ± 0.08; pIC50(R) = 4.48 ± 0.07; pIC50(S) = 4.33 ± 0.06.)
Citalopram inhibits ATP and ADP release. The effect of (RS)-citalopram on collagen-induced ATP and 
ADP release from dense granules was measured (N = 5). Washed platelets were pre-treated with citalopram (0, 10, 
20, 50, 100 and 200 µM) before stimulation with collagen (1 µg mL−1) for 6 min, under aggregometry conditions. 
Figure 4a shows high pressure liquid chromatography (HPLC) chromatograms of ATP and ADP, which had reten-
tion times of 3.4 and 4.5 min, respectively. Known standards were used to create a calibration curve of peak area 
under the curve (AUC) versus nucleotide concentration (Fig. 4b), which was used to determine sample nucle-
otide levels in the presence of varying concentrations of (RS)-citalopram (Fig. 4c and d). ATP and ADP release 
were reduced in a concentration-dependent manner by (RS)-citalopram. pIC50 values were ATP = 4.54 ± 0.06; 
ADP = 4.51 ± 0.06 (mean ± SE, N = 5) (Table 1).
Citalopram inhibits tyrosine phosphorylation of PLCγ2, Src family kinases and LAT. Preliminary 
non-blinded experiments (Fig. 5a, Supplementary Fig. S1) indicated that citalopram reduced whole cell tyrosine phos-
phorylation, including the 10–15 kDa Fc receptor gamma chain (FcRγ), and site-specific tyrosine phosphorylation of 
Src family kinases (SFK) (Y416), Linker of Activated T cells (LAT) (Y200) and phospholipase Cγ2 (PLCγ2) (Y1217), 
all on residues associated with their activation. SFK, LAT and PLCγ2 are situated respectively at proximal, intermedi-
ate and distal positions in the GPVI signalling pathway, with PLCγ2 mediating the release of calcium from intracel-
lular stores into the cytosol. Protein samples from subsequent experiments were randomly loaded into pre-cast gels 
in a blinded fashion and membranes probed for PLCγ2 (N = 5) and LAT (N = 5) (Supplementary Fig. S2) and SFK 
(N = 4) (Supplementary Fig. S3). In each experiment, basal phosphorylation (cross-linked collagen-related peptide 
(CRPXL) = 0) and concentration-inhibition curves (CRPXL = 5 µg mL−1; (RS)-citalopram = 0, 1, 10, 20, 50, 100 and 
200 µM) were determined and analysed using non-linear mixed effects modelling (Fig. 5b). pIC50 values are in Table 1. 
www.nature.com/scientificreports/
3SCiENtifiC REPORTS |  (2018) 8:3494  | DOI:10.1038/s41598-018-21348-3
(RS)-citalopram inhibited CRPXL-induced tyrosine phosphorylation of PLCγ2 (P = 2 × 10−13), SFK (P = 7 × 10−25) 
and LAT (P = 4 × 10−10). No phosphorylated PLCγ2 or LAT was detected in unstimulated platelets, although there 
was a basal signal for phosphorylated SFK (Fig. 5b). There was no relationship between CRPXL or (RS)-citalopram and 
total levels of PLCγ2 (P = 0.30), Src (P = 0.84) or LAT (P = 0.30) (Fig. 5b).
Citalopram blocks uptake of 5-HT into platelets. Experiments were designed to measure the inhib-
itory potency (pIC50) of (RS)-, (R)- and (S)-citalopram on 5-HT uptake into platelets. 5-HT (1 µM) was added 
to washed platelets (2.00 × 108 mL−1) and its extracellular concentration measured over time. The decline in 
Figure 1. Inhibition by citalopram of platelet aggregation induced by Horm collagen (N = 7 blood donors) and 
U46619 (N = 6 blood donors). (a) Example aggregation traces, illustrating concentration-dependent inhibition 
of collagen- and U46619-induced platelet aggregation by (RS)-citalopram. Arrowheads indicate the addition 
of agonist. (b) Collagen and U46619 concentration-response curves showing inhibition by (RS)-citalopram 
of the maximum extent of aggregation. (c) (RS)-, (R)- and (S)-citalopram inhibited the maximum extent of 
aggregation induced by 1 µg mL−1 collagen or 0.2 µM U46619 with similar inhibitory potencies (pIC50). 3-way 
ANOVA was performed with IBM SPSS v.23 (Effect 1 (fixed) = citalopram preparation {(RS), (R), (S)}; Effect 
2 (fixed) = agonist {collagen, U46619}; Effect 3 (random) = donor {N = 7 (collagen), N = 6 (U46619)}). The 
results indicated no difference in the pIC50 of the three citalopram preparations (P = 0.95, F = 0.054, degrees of 
freedom (df) = 2, 27. H0: μRS = μR = μS; H1: μRS ≠ μR ≠ μS). Statistical evidence for a difference in the pIC50 values 
between collagen and U46619 was weak (P = 0.080, F = 3.314, df = 1, 27. H0: μcollagen = μU46619;  
H1: μcollagen ≠ μU46619).
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Function Agonist/ligand
pIC50 (mean ± SE (N))
(RS) (R) (S)
Aggregation
Collagen 4.31 ± 0.21 (7) 4.29 ± 0.36 (7) 4.25 ± 0.21 (7)
U46619 4.15 ± 0.27 (6) 4.12 ± 0.22 (6) 4.20 ± 0.29 (6)
Adhesion
Collagen 3.76 ± 0.02 (9) 3.77 ± 0.05 (4) 3.72 ± 0.01 (4)
CRP 3.78 ± 0.04 (8) 3.81 ± 0.05 (4) 3.74 ± 0.01 (4)
Fibrinogen 4.00 ± 0.07 (9) 3.92 ± 0.04 (4) 3.92 ± 0.05 (4)
GFOGER 3.97 ± 0.03 (9) 4.02 ± 0.05 (4) 3.95 ± 0.03 (4)
TxB2 synthesis Collagen 4.77 ± 0.08 (6) 4.68 ± 0.04 (6) 4.70 ± 0.09 (6)
Release (ATP) 
Release (ADP)
Collagen 
Collagen
4.54 ± 0.06 (5) 
4.51 ± 0.06 (5)
PLCγ2 (Y1217)  
SFK (Y416)  
LAT (Y200)
CRPXL  
CRPXL  
CRPXL
4.28 ± 0.03 (5) 
4.24 ± 0.03 (4) 
3.77 ± 0.03 (5)
5-HT uptake 5-HT 8.34 ± 0.05 (13) 7.37 ± 0.05 (13) 8.60 ± 0.05 (13)
Table 1. Summary pIC50 values (mean ± SE (N)) for (RS)-, (R)- and (S)-citalopram on platelet aggregation, 
static adhesion to collagen, TxB2 generation, ATP and ADP release, site-specific protein tyrosine 
phosphorylation and 5-HT uptake.
Figure 2. Inhibition by citalopram under static conditions of platelet adhesion to Horm collagen, CRP, fibrinogen 
and GFOGER. BSA and GPP were used as negative controls. Full concentration-inhibition curves were obtained 
for (RS)-, (R)- and (S)-citalopram (0–300 µM) for each ligand. 3-way ANOVA was performed with IBM SPSS 
v.23 (Effect 1 (fixed) = citalopram preparation {(RS), (R), (S)}; Effect 2 (fixed) = ligand {collagen, CRP, fibrinogen, 
GFOGER}; Effect 3 (random) = donor {N = 8–9 (RS) and N = 4 (R), (S)}). The results indicated no difference in 
the pIC50 of the three citalopram preparations (P = 0.32, F = 1.18, df = 2, 44. H0: μRS = μR = μS; H1: μRS ≠ μR ≠ μS).
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concentration followed a first order pattern (see Eq. 2) and hence each kinetic profile (n = 6–12 time points per 
profile) yielded a single rate constant for uptake (ku). The rate constant is the probability of 5-HT uptake per unit 
time and is therefore directly proportional to the level of SERT activity. Consequently, a 50% reduction in ku from 
baseline indicated 50% citalopram binding.
Figure 3. Inhibition by citalopram of TxB2 generation. Platelets were stimulated with collagen (1 µg mL−1) 
for 6 min under aggregometry conditions (37 °C, 1,000 rpm) and supernatants isolated. Full concentration-
inhibition curves were obtained for (RS)-, (R)- and (S)-citalopram (0–200 µM). 2-way ANOVA was performed 
with IBM SPSS v.23: (Effect 1 (fixed) = citalopram {(RS), (R), (S)}; Effect 2 (random) = donor {N = 6}). The 
results indicated no difference in the pIC50 of the three citalopram preparations (P = 0.60, F = 0.54, df = 2, 10. 
H0: μRS = μR = μS; H1: μRS ≠ μR ≠ μS).
Figure 4. Inhibition by citalopram of collagen-induced release of ATP and ADP from platelets. WP were 
stimulated with collagen (1 μg mL−1) for 6 min under aggregometry conditions (37 °C, 1,000 rpm), supernatants 
collected, and levels of ATP and ADP quantified using HPLC and absorbance detection at 254 nm (N = 5 
blood donors). (a) Example HPLC chromatograms, showing known ATP and ADP peaks. (b) Peak AUC was 
plotted against nucleotide concentration to generate standard curves. (c) Example HPLC chromatograms from 
supernatants of collagen-stimulated platelets pre-incubated with (RS)-citalopram. (d) Concentration-inhibition 
curves for (RS)-citalopram (0–200 µM).
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Figure 5. Whole cell tyrosine phosphorylation (4G10) and site-specific phosphorylation of Src family kinases 
(SFK), LAT and PLCγ2. Platelets were stimulated with 5 µg mL−1 CRPXL for 6 min under aggregometry 
conditions in the presence of GR 144053 (2 µM) to prevent aggregation and facilitate solubilisation of 
protein. (a) Images from non-blinded pilot experiments show the effect of (RS)-citalopram on whole cell 
tyrosine phosphorylation and site-specific phosphorylation of PLCγ2, SFK and LAT. The whole cell tyrosine 
phosphorylation blot is one of two repeats. The phospho-specific blots are from additional pilot experiments. 
Images have been cropped from four different blots. Images of full-length blots from these experiments 
are presented in Supplementary Fig. S1. (b) Densitometric quantification from blinded and randomised 
experiments measuring site-specific phosphorylation of PLCγ2 (N = 5), SFK (N = 4) and LAT (N = 5) in resting 
or stimulated platelets. Blots are shown in Supplementary Figs. S2 and S3. Dashed lines (mean) and grey area 
(±SE) indicate background signal on the developed X-ray films. Lower panels represent total protein levels 
from the same samples. Concentration-responses were modelled using NONMEM 7.3 to accommodate random 
between experiment variability often associated with Western Blotting. Confirmation of the phosphorylation 
response was performed using likelihood ratio tests by comparing the following statistical hypotheses: H0: 
Max = Min and H1: Max ≠ Min. Results were: phospho-PLC (Y1217), P = 2 × 10−13 (χ2 = 65.1, df = 4); 
phospho-SFK (Y416), P = 7 × 10−25 (χ2 = 115.7, df = 3); phospho-LAT (Y200), P = 4 × 10−10 (χ2 = 49.8, df = 4). 
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Figure 6a and b show HPLC chromatogram peaks from known 5-HT concentrations (retention time of 
4.25 min) and a standard curve for 5-HT from one experimental day, respectively. Figure 6c shows a test HPLC 
chromatogram from platelet supernatants. The concentrations of supernatant 5-HT were derived from the peak 
AUC and the standard curve.
Rate constants (ku) were obtained for (RS)-, (R)- and (S)-citalopram over a range of concentrations, which 
varied depending on the citalopram isomer (Fig. 6d). Owing to logistical constraints, it was not possible to collect 
data for all conditions on each experimental day. In total, 76 rate constants from 11 donors were obtained on 14 
separate occasions. Data from one day/donor (comprising 4 rate constants) were excluded from the final analysis 
as a hyper-functional outlier, lying 7 SDs beyond the basal range as defined by all the other data. All remaining 
data for the three citalopram inhibition curves were modelled simultaneously to the 4PL using NONMEM 7.3, 
allowing estimation of the random variance in basal activity between different experimental days.
Basal ku (mean ± SE) was 4.60 ± 0.23 hr−1 and the inter-experimental standard deviation ± SE was 0.75 ± 0.17 hr−1. 
Citalopram abolished uptake (Max(RS) = 0.09 ± 0.04; Max(R) = −0.02 ± 0.11; Max(S) = 0.01 ± 0.05) with Hill 
coefficients close to unity (nH(RS) = 1.08 ± 0.09; nH(R) = 1.03 ± 0.12; nH(S) = 1.18 ± 0.12) (P = 0.099: see Fig. 6e 
for further detail). This is consistent with non-cooperative 1:1 binding of citalopram to SERT, thereby caus-
ing complete blockade of 5-HT transport. The isomers had different inhibitory potencies: (S)-citalopram 
(pIC50(S) = 8.60 ± 0.05) was approximately 17-fold more potent than (R)-citalopram (pIC50(R) = 7.37 ± 0.05) and 
(RS)-citalopram (pIC50(RS) = 8.34 ± 0.05) was approximately 1.8-fold less potent than (S)-citalopram, suggesting 
that the inhibitory activity of (RS)-citalopram was predominantly caused by (S)-citalopram. The mechanistic 
significance of these data is discussed below.
Cytotoxic effects of citalopram on platelets. An experiment (N = 5 donors) was designed to determine 
whether the citalopram concentrations used throughout this study were cytotoxic to platelets. Washed platelets 
(2.00 × 108 mL−1) were incubated for 10 min with citalopram (0, 10, 20, 50, 100 and 200 μM) and levels of super-
natant lactate dehydrogenase (LDH) quantified. Citalopram did not cause LDH release at any tested concentra-
tion (Fig. 7).
Discussion
This is not the first time that citalopram or other SSRIs have been shown to inhibit platelet function in vitro2,22,23. 
However, implicit in some previous studies is the mechanistic conclusion that functional inhibition of platelets 
by SSRIs is due to SERT inhibition. The expression on platelets of SERT31, the molecular target of SSRIs, lends 
credibility to this conclusion. The principal objective of our study was to determine whether functional inhibition 
of platelets by citalopram could be mechanistically linked with SERT blockade.
Citalopram is a racemate, comprising low (R) and high (S) potency isomers. We quantified the inhibitory 
potency of the isomers and the racemate against different platelet functions and 5-HT uptake using the same 
preparation of platelets to enable direct comparison of the results (Fig. 8 and Table 1). Our data confirm the dif-
ference in potency between (R)- and (S)-isomers in inhibiting 5-HT uptake28. By contrast, there was no difference 
in the potencies of the isomers in inhibiting platelet aggregation, adhesion or TxA2 synthesis. Furthermore, the 
concentrations required to inhibit all platelet functions were substantially in excess of those required to inhibit 
SERT. At concentrations less than 1 µM, 5-HT uptake was completely blocked by both (R)- and (S)-isomers, 
whereas there was no indication of functional inhibition. High concentrations of citalopram that blocked platelet 
function did not cause cell destruction (Fig. 7), suggesting that the observed inhibition is not a non-specific toxic 
effect. We therefore conclude that platelet inhibition by citalopram in vitro is not dependent on the inhibition of 
SERT-mediated 5-HT uptake, and that other mechanisms must be identified to explain these antiplatelet effects 
of citalopram.
Our results are partly consistent with those from earlier studies22,23. Contrary to previous claims22, we demon-
strate that platelet inhibition by citalopram is not collagen-specific, since it clearly inhibits U46619-induced 
aggregation. Furthermore, their observation22 that citalopram did not inhibit collagen-induced PAC-1 binding 
to integrin αIIbβ3 was surprising, given that citalopram inhibited collagen-induced aggregation, and especially 
since it did block convulxin-induced PAC-1 binding22. Tseng et al. suggested that the GPVI pathway was blocked, 
but that collagen might act via a citalopram-insensitive pathway, for example, α2β1 signalling. By contrast, our 
results with collagen and the GPVI-selective ligand CRPXL provide no reason to suppose that inhibition of 
collagen-induced responses by citalopram is mediated exclusively via disruption of α2β1 signalling.
It has previously been reported that citalopram is an allosteric serotonin reuptake inhibitor32. A complex 
mechanism of action has been proposed with two distinct binding loci, a primary and an allosteric site, on 
SERT. It has been suggested that binding of either (R)- or (S)-isomers to an allosteric site has differential effects 
on the primary binding site33, thus providing a mechanistic explanation for the more rapid onset of action of 
(S)-citalopram in animal models of depression34, and greater potency in clinical trials35. By contrast, our data 
are consistent with a simple mechanism of action in which both (R)- and (S)-isomers bind to the same site on 
SERT but with differing affinities. Hill coefficients of unity and complete inhibition of 5-HT uptake suggest that 
non-cooperative binding of citalopram completely blocks SERT. Inhibition caused by simultaneous application of 
two different drugs differs when those drugs either compete for the same site (syntopic model) or bind to separate 
sites (allotopic model)36. We fitted our 5-HT uptake data to both syntopic and allotopic models using NONMEM: 
Evaluation of total protein levels was performed by comparing the hypotheses: H0: Max = Min = Basal; and H1: 
Max ≠ Min ≠ Basal (Basal = signal when CRP = 0 µg ml−1). Results were: PLC, P = 0.30 (χ2 = 6.04, df = 5); Src, 
P = 0.84 (χ2 = 1.39, df = 4); LAT, P = 0.30 (χ2 = 4.89, df = 4).
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in both cases the number of estimated parameters was the same, but the predicted effect of the racemic mixture 
differed between the two models. The difference in the Bayes Information Criterion37 for the two models was 14.0, 
with the syntopic model having the lower value. Following the convention of Kass and Raftery38, this constitutes 
“very strong” evidence in favour of the syntopic model. Taken altogether, our findings suggest that at concentra-
tions of up to 1 µM, inhibition of 5-HT uptake by citalopram is consistent with a simple non-cooperative binding 
model in which the (R)- and (S)-isomers bind to the same site but with different affinities.
Both (R)- and (S)-citalopram slow the dissociation of bound [3H]-(S)-citalopram from SERT at concentra-
tions from 1–200 µM39,40, levels in excess of those required to block 5-HT uptake. A daily dose of 30–60 mg 
citalopram gives steady-state plasma concentrations of 120–600 nM41 and approximately 50–80% of citalopram 
is bound to plasma proteins41,42. Therefore, clinical doses of either (RS)- or (S)-citalopram generate plasma con-
centrations that will substantially block 5-HT uptake, but will have neither the allosteric effect on SERT, nor the 
antiplatelet effects reported in our study. It is therefore unlikely that a typical therapeutic regime of citalopram will 
have any anti-haemostatic or anti-thrombotic effect as a consequence of the functional inhibitory effects we have 
described. Long-term treatment with citalopram depletes platelet 5-HT2,27 and this may provide an alternative 
mechanism for any observed clinical effects on thrombosis and haemostasis.
Although there is no direct relationship between blockade of 5-HT uptake and platelet inhibition, it remains 
possible that SERT blockade is permissive for additional mechanisms that citalopram may exert at higher con-
centrations. However, we do not consider this to be likely and have no evidence that positively supports this 
hypothesis. Interestingly, the range of citalopram concentrations that exert an allosteric effect on SERT, whilst not 
of clinical significance, is similar to the range within which we observe platelet functional inhibition.
Other mechanistic associations with SERT have been described that may contribute to the functional effects 
of citalopram, including P2Y12 signalling23, 5-HT2A receptor desensitisation43 and integrin αIIbβ324. In the case 
of αIIbβ3, co-expression in HEK293 cells of human SERT with either Leu33 or Pro33 variants of the β3 integrin 
resulted in differential surface expression of SERT and a consequent effect on 5-HT transport. Similarly, platelets 
from Leu33 and Pro33 homozygotes also showed differential sub-cellular distribution of SERT with lower rel-
ative surface expression in non-mutant Leu33 individuals24. This, and their observation that fibrinogen-bound 
Figure 6. Inhibition of 5-HT uptake into platelets by citalopram. (a) Example HPLC chromatograms, 
showing peaks for known concentrations of 5-HT. (b) Peak AUCs, detected at 276 nm, were plotted against 
standard 5-HT concentrations to construct a calibration curve. (c) Example chromatograms used to quantify 
the supernatant 5-HT concentration 30 min after the addition of 1 µM 5-HT to WP. (d) Profiles showing the 
reduction in supernatant 5-HT over time. Uptake was blocked by increasing concentrations of (RS)-, (R)- and 
(S)-citalopram. Kinetic profiles (each with 6–12 time points) were used to determine rate constants of uptake 
(ku) under differing citalopram conditions. (e) The concentration-dependent effect of (RS)-, (R)- and (S)-
citalopram (0–1,000 nM) on ku was fitted to the 4PL model using NONMEM 7.3 and nested models compared 
using Likelihood Ratio Tests. Each citalopram preparation abolished 5-HT uptake in a manner consistent with 
non-cooperative 1:1 binding (P = 0.099, LRT, χ2 = 10.7, df = 6. H0: nH = 1, Max = 0; H0: nH ≠ 1, Max ≠ 0 for 
each preparations of citalopram. N = 13 separate experiments).
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platelets had a greater rate of 5-HT uptake suggest a functional interaction between SERT and αIIbβ3, which may 
provide a mechanistic basis for the actions of citalopram in platelets. However, in a study on SERT-deficient 
murine platelets, a physical interaction between SERT and β3 integrin was found to be not essential for inside-out 
integrin activation44. These conflicting findings bring into question the significance of any association between 
SERT and αIIbβ3, at least in mouse platelets, and therefore do not provide a clear mechanistic basis for the actions 
of citalopram.
Citalopram has been reported to have SERT-independent effects in the nervous system via an action on 
sigma-1 (σ1) receptors45. Other SSRIs also have affinity for σ1 receptors46 and peptide sequences from the σ1 
receptor have been identified in platelets47. These observations suggest that the σ1 receptor may be a target medi-
ating the SERT-independent effects of citalopram in platelets. However, Bonnin et al. observed no effect with 
(S)-citalopram and concluded that SERT-independent action was mediated by the (R)-isomer. This is clearly not 
Figure 7. Micromolar concentrations of citalopram do not cause cytotoxicity, as indicated by LDH release from 
platelets. Platelets were incubated for 10 min with (RS)-citalopram (0–200 µM). Calcium-free Tyrodes (CFT) 
and lysed platelets were used as negative and positive controls, respectively (N = 5 blood donors).
Figure 8. Summary results, showing the difference in pIC50 values (mean ± SE) between the inhibition of 5-HT 
uptake by citalopram isomers (Fig. 6) and their inhibition of platelet aggregation (Fig. 1), adhesion to Horm 
collagen (Fig. 2), TxB2 generation (Fig. 3), nucleotide release from dense granules (Fig. 4) and the site-specific 
phosphorylation of Src family kinases (SFK), LAT and PLCγ2 (Fig. 5).
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consistent with our observations, and the reported Ki of 0.3 µM of citalopram for σ1 receptors46 further under-
mines the hypothesis that σ1 may be mediating the effects of citalopram in platelets.
Although our study was designed principally to address the question of the role of SERT, there are clues in the 
data that point to potential novel mechanisms of action. Figure 1b and c clearly indicate that citalopram is more 
potent at inhibiting collagen than U46619-induced aggregation. The effect of 20 µM citalopram may therefore 
be on a collagen-specific mechanism. The effect of 20 and 50 µM citalopram on collagen looks competitive, sug-
gesting an action at or close to the level of the receptor, GPVI. Inhibition of phosphorylation of GPVI signalling 
proteins including PLCγ2, LAT, SFKs and FcRγ chain also supports this hypothesis. At 100 µM citalopram, inhi-
bition of U46619 is clear and of collagen is exaggerated (Fig. 1b), suggesting a distinct mechanism. The signalling 
pathways of GPVI and the thromboxane receptor converge with an elevation of intracellular calcium. The data 
may therefore indicate an effect of citalopram on either calcium signalling or a process further downstream at 
concentrations higher than those required to inhibit GPVI signalling. The collapse of the U46619 response at 
200 µM is also consistent with this hypothesis. Preliminary data that support these hypotheses have recently been 
presented48.
The platelet inhibitory effects of citalopram occur at relatively high concentrations, and it is therefore unlikely 
that these effects could be exploited clinically. However, after identifying a mechanism, citalopram could serve as 
a chemical starting point for the development of more potent and selective inhibitors of that mechanism, just as 
ATP, a clinically impractical, non-selective, low potency inhibitor of the P2T receptor49,50 became the starting point 
for a drug discovery project that produced the P2Y12 antagonist ticagrelor51. Hence, the study of the pharmacol-
ogy of low potency compounds can be both biologically enlightening and practically beneficial.
In summary, we have shown that inhibition of SERT-dependent 5-HT uptake by citalopram does not corre-
late with inhibition of platelet function in vitro. Furthermore, the mechanisms that underlie citalopram-induced 
platelet inhibition in vitro are unlikely to influence haemostasis and thrombosis in vivo. Long-term citalopram 
treatment, depletion of platelet 5-HT and disruption of 5-HT-mediated effects on blood vessels may do so. We 
therefore conclude that the antiplatelet effects of citalopram observed at micromolar concentrations in vitro must 
be mediated by pharmacological mechanisms distinct from SERT inhibition and the blockade of 5-HT uptake. 
Further investigations are ongoing to identify potential molecular targets in platelets responsible for these effects 
of citalopram.
Materials and Methods
Materials. Fibrinogen, p-nitrophenyl phosphate, prostaglandin E1, indomethacin, U46619 (a TxA2 mimetic), 
citric acid, EDTA, trisodium citrate, ATP, ADP and potassium phosphate dibasic were from Sigma (Poole, U.K.). 
EGTA was from Calbiochem (Nottingham, U.K.). (RS)-citalopram and (S)-citalopram were from Cambridge 
Bioscience (Cambridge, U.K.). (R)-citalopram was from Insight Biotechnology (Wembley, U.K.). Acetonitrile 
and potassium phosphate monobasic were from Fisher Scientific (Loughborough, U.K.). 5-HT was from Alfa 
Aesar (Lancashire, U.K.). Horm collagen was from Takeda (Linz, Austria). BSA was from G.E. Healthcare 
(Buckinghamshire, U.K.). GR 144053 was from Tocris Bioscience (Bristol, U.K.). The following synthetic colla-
gen-mimetic peptides were synthesised in the laboratory of Professor Richard Farndale (University of Cambridge, 
U.K.): collagen-related peptide (CRP: sequence = GCO(GPO)10GCOG-NH2, O = hydroxyproline); cross-linked 
CRP (CRPXL); GPP (sequence = GPC(GPP)10GPC-NH2); and GFOGER (sequence = GPC(GPP)5GFOGER 
(GPP)5GPC-NH2)30. Antibodies against phospho-SFK (Y416) (#2101 S)52, Src (#2108 S)52 and phospho-PLCγ2 
(Y1217) (#3871)53 were from Cell Signalling Technology (Danvers, MA, U.S.A.). Antibodies against LAT (#06-
807)54 and phospho-tyrosine (4G10) (#05-321)55 were from Millipore (Watford, U.K.). Antibodies against phos-
pho-LAT (Y200) (#ab68139)56 were from Abcam (Cambridge, U.K.). Antibodies against PLCγ2 (#sc-407)57 were 
from Santa Cruz (Wembley, U.K.). HRP-conjugated mouse (#P0447)58 and rabbit (#P0448)58 secondary antibod-
ies were from Dako (Ely, U.K.).
Washed platelet preparation. Donation of fresh blood from healthy, consenting human volunteers was 
approved by the University of Cambridge Human Biology Research Ethics Committee (Ref: HBREC.2015.18). 
Prior to any blood donation, informed consent was obtained from each blood donor. The consent form was 
signed by both the donor and one of the project supervisors (G.E.J. or S.O.S.). A fresh consent form is signed 
annually. On the occasion of each donation of blood, a donation record form was signed by both the donor and 
the phlebotomist (G.E.J., S.O.S. or H.G.R.). Collection of blood from donors, its use and subsequent disposal were 
performed in accordance with relevant guidelines and regulations.
Blood was drawn into syringes containing trisodium citrate (final concentration of 11 mM) and centrifuged 
(500 × g, 5 min) to obtain platelet-rich plasma. Following addition of prostaglandin E1 (final concentration of 
1 μM), platelet-rich plasma was centrifuged (900 × g, 15 min) and the resulting platelet pellet re-suspended in 
a modified calcium-free Tyrode’s buffer (CFT; 137 mM NaCl, 11.9 mM NaHCO3, 0.4 mM NaH2PO4, 2.7 mM 
KCl, 1.1 mM MgCl2, 5.6 mM glucose; pH = 7.4). Platelet counts were adjusted using a Z2 COULTER COUNTER 
(Beckman Coulter, High Wycombe, U.K.). Platelets were usually pre-treated with (RS)-, (R)- or (S)-citalopram 
for approximately 3–5 mins before each experiment. For the aggregation experiments, citalopram was simulta-
neously added to all washed platelet samples in advance of the measurements, and therefore some samples were 
incubated for longer periods of time, up to 3 hours. Preliminary data gave no indication that inhibitory effect of 
citalopram was time-dependent within this time-scale.
Platelet aggregometry. Platelet aggregation was measured by turbidimetric aggregometry59,60, using 
two Aggregation Remote Analyser Modules (AggRAM) with HemoRAM software (v1.2) (Helena Biosciences, 
Newcastle, U.K.). Washed platelets (WP) (247.5 µL, 2.00 × 108 mL−1) were aliquoted into glass cuvettes containing 
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magnetic stir bars. 2.5 µL agonist was added and aggregation recorded at 37 °C with a stir speed of 1,000 rpm. The 
maximum extent of aggregation over 6 min was determined60.
Static platelet adhesion. Platelet adhesion under static conditions was measured by detecting acid phos-
phatase levels in platelet lysates61,62. 100 μL of adhesive ligand (10 μg mL−1 in saline or 0.01 M acetic acid) was 
incubated in Immulon-2HB 96-well flat bottom plates overnight at 4 °C. Ligands were randomly assigned to dif-
ferent rows for each experiment. Excess ligand was discarded, and the wells blocked with 175 μL BSA (5% [w/v] in 
CFT) for 1 hour. Wells were then washed 3 times with BSA (0.1% [w/v] in CFT). 50 µL WP (1.25 × 108 mL−1) were 
added to wells and left at room temperature (RT) for 1 hour. WP containing different drug concentrations were 
randomly assigned to different columns for each experiment. Excess WP were discarded and the wells washed a 
further three times, followed by addition to each well of 150 μL citrate lysis buffer (3.53 mM p-nitrophenyl phos-
phate, 71.4 mM trisodium citrate, 28.55 mM citric acid, 0.1% [v/v] Triton X-100, pH = 5.4). After 1 hour incuba-
tion at RT, 100 μL of 2 M NaOH was added to each well and absorbance measured at 405 nm using an ELx808 
plate reader (Biotek, Swindon, U.K.).
Thromboxane A2 synthesis. On activation, platelets produce the pro-aggregatory, vasoconstrictor TxA2. 
Inhibition of TxA2 synthesis is thought to underlie the anti-thrombotic effects of aspirin. TxA2 is rapidly hydro-
lysed in aqueous media to TxB2, which is stable. We measured TxB2 generation using the competitive Cayman 
TxB2 Express ELISA kit (Cambridge Bioscience, Cambridge, U.K.).
WP (247.5 µL, 2.00 × 108 mL−1) were activated as for aggregometry. 6 min after agonist addition, the STOP 
solution was added, samples were immediately centrifuged (12,000 rpm, 2 min) and the supernatants frozen at 
−80 °C. Samples were later thawed and diluted 1:40 or 1:200 in ELISA buffer (100 mM phosphate, 0.1% [w/v] 
BSA, 400 mM NaCl, 1 mM EDTA, 0.01% [w/v] sodium azide) and 50 µL added to wells of a polyclonal goat 
anti-mouse IgG-coated plate. 50 µL of TxB2 standards were aliquoted to determine the relationship between 
absorbance and TxB2 concentration. 50 µL of TxB2-acetylcholinesterase tracer and 50 µL of anti-TxB2 monoclonal 
antibody were added to each well and incubated for 2 hours at RT. Wells were washed four times with wash buffer 
and incubated with 200 µL Ellman’s Reagent under dark conditions. Absorbance at 405 nm was measured period-
ically using a Tecan Sunrise absorbance microplate reader (Tecan U.K., Reading, U.K.), until the absorbances of 
wells containing no sample TxB2 were in the range of 0.3–1.5 absorbance units (A.U.).
Absorbance values for TxB2 standards were fitted to a 4PL model and test sample values were converted to 
TxB2 concentrations using the inverse function.
Platelet nucleotide release. WP (247.5 µL, 2.00 × 108 mL−1) were activated by the addition of 2.5 µL of 
agonist in the AggRAM modules (37 °C, 1,000 rpm). 50 µL of a STOP solution (final concentration = 5 mM EGTA, 
16.6 μM indomethacin) was added after 6 min to minimise further nucleotide release. Samples were immediately 
centrifuged (1 min, 13,000 rpm) and supernatants collected and frozen.
Supernatant concentrations of ATP and ADP were quantified using HPLC with a Waters 2795 Separations 
Module and a Waters 2847 Dual λ Absorbance Detector (Waters, Hertfordshire, U.K.). Nucleotides were sepa-
rated using a gradient method on a reversed phase C18 column with polar endcapping to tolerate a 100% aqueous 
phase (Synergi Hydro-RP: 250 × 4.6 mm, 4 μm beads, 80 Å pore size) (product code 00G-4375-E0, Phenomenex, 
Cheshire, U.K.). Two mobile phases were used, a phosphate buffer (2.2 mM K2HPO4, 47.8 mM KH2PO4; 
pH = 5.45) and acetonitrile. Nucleotides were separated over 6 min at a constant flow rate of 1.7 mL min−1. Details 
of the gradient method are in Supplementary Table S1. Peaks for ATP and ADP were detected at 254 nm, with 
retention times of 3.4 and 4.5 min, respectively. Chromatograms were analysed using N2000 Chromatography 
Data System (Tianjin University, China). Nucleotide levels were quantified as AUC of the peaks, and converted 
into concentrations using linear ATP and ADP standard curves, prepared on each analytical day.
Protein tyrosine phosphorylation. WP (247.5 µL, 2.00 × 108 mL−1) were stimulated with CRPXL 
(5 µg mL−1) in AggRAM modules (37 °C, 1,000 rpm) for 6 min in the presence of GR 144053 (2 µM), an integ-
rin αIIbβ3 antagonist, to prevent aggregation. WP were diluted 5:1 in Laemmli sample buffer (final concentra-
tions = 25 mM Tris HCl, 0.4% [v/v] glycerol, 0.8% [w/v] SDS, 1% [v/v] mercaptoethanol, 0.01% [w/v] brilliant 
blue) and heated for 10 min at approximately 100 °C. Molecular weight markers (Precision plus protein standards, 
Bio-Rad Laboratories, Hertfordshire, U.K.) were added to wells 1 and 10, and protein samples randomly assigned 
and added in a blinded fashion to wells 2–9 of 10 well 4–12% pre-cast NuPage Bis-Tris gels (Invitrogen, Paisley, 
U.K.). Proteins were separated by SDS/PAGE and transferred (20 volts, overnight, 4 °C) onto PVDF membranes 
(Millipore, Watford, U.K.) immersed in transfer buffer (25 mM Tris base, 192 mM glycine, 0.5% [w/v] SDS, 17% 
[v/v] methanol). Non-specific antibody binding was minimised by incubating membranes with blocking buffer 
(10% [w/v] BSA, 20 mM Tris base, 137 mM NaCl, 0.1% [v/v] Tween-20, pH = 7.6) for 1 hour at RT. Some mem-
branes were cut into two parts, which were probed separately with different primary antibodies for 2 hours at RT 
(1:1000), followed by incubation with HRP-conjugated secondary antibody (1:5000) for 1 hour at RT. Enhanced 
chemiluminescence (ECL) was used to detect protein bands with Amersham ECL Prime Western Blotting 
Detection Reagent and Amersham Hyperfilm ECL (G.E. Healthcare Life Sciences, Buckinghamshire, U.K.). Films 
were developed using a Fuji medical film processor FPM-100A (FUJIFILM U.K. Ltd., Bedford, U.K.). Different 
film exposure times were used for each blot and those generating the greatest contrast between the bands were 
selected for subsequent quantification.
Developed X-ray films were scanned using a Xerox WorkCentre 7855 photocopier (Settings: greyscale; default 
for brightness/sharpness/saturation; 100% zoom; 600 dpi) to generate JPEG image files. Unprocessed image files 
were opened into ImageJ (v1.50) and no adjustments (e.g., brightness/sharpness/saturation) were made. Protein 
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bands were quantified as follows: identical areas (height (100) × width (150) = 15,000 pixels) were drawn around 
each protein band and the density of all pixels (scale 0–255 each) summed. The integrated density of each area was 
therefore quantified on a scale from 0 (totally white) to 3,825,000 (totally black). Values are presented as % black. 
Background density levels were determined (approx. 45–48% black), representing no protein signal. Data were 
not un-blinded until quantification of all blots was complete.
5-HT uptake into platelets. Platelets take up extracellular 5-HT via SERT and store it in dense granules. 
SERT activity was quantified by monitoring the reduction in extracellular concentration of 5-HT following the 
addition of 1 μM 5-HT to WP (2.00 × 108 mL−1). After addition of 5-HT, aliquots of WP were removed at 5 min 
intervals, added to a STOP solution to minimise subsequent uptake, immediately centrifuged (13,000 rpm, 1 min, 
RT), and the supernatant frozen.
HPLC (see above) was used to separate and quantify 5-HT from WP supernatants. A reversed phase C18 col-
umn (Kinetex: 250 × 4.6 mm, 5 μm beads, 100 Å pore size) (Product code 00G-4601-E0, Phenomenex, Cheshire, 
U.K.) and isocratic method (mobile phase: 94% [v/v] phosphate buffer (18.4 mM citric acid, 83.2 mM K2HPO4; 
pH = 6.6) and 6% [v/v] acetonitrile) were used at 40 °C with a flow rate of 1 mL min−1. 5-HT appeared as a peak 
at 4.25 min, detectable at 276 nm. Chromatograms were analysed using N2000 Chromatography Data System 
(Tianjin University, China). 5-HT standards in CFT were measured on each experimental day to determine 5-HT 
concentrations in the WP supernatants.
Lactate dehydrogenase cytotoxicity assay. Lactate dehydrogenase (LDH) release from WP was 
determined as an indicator for drug-induced cytotoxicity and cytolysis, using a Pierce LDH activity assay kit 
(Thermo Fisher Scientific, Loughborough, U.K.). WP (250 µL, 2.00 × 108 mL−1) were treated with citalopram for 
10 min, supernatants isolated following centrifugation (13,000 rpm, 1 min, RT) and 50 µL aliquoted into wells of 
an Immulon-2HB 96-well flat-bottom plate. 50 µL of the proprietary reaction mixture (Thermo Fisher, product 
code: 1862887) was added to each well for 30 min. 50 µL of the proprietary stop solution (Thermo Fisher, product 
code: 1862880) terminated the reaction, and background absorbance at 680 nm was subtracted from the absorb-
ance at 490 nm. Measurements were taken using a Tecan Sunrise absorbance microplate reader (Tecan U.K., 
Reading, U.K.).
Data modelling and statistical analysis. Concentration-response data were modelled using a 
four-parameter logistic (4PL) model60,63:
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where: RPRED = predicted response (dependent variable); [A] = agent concentration (independent variable); 
Min = response when [A] = 0; Max = response when [A] = ∞; pA50 = −log [A] (expressed in units of mol.L−1) 
when RPRED = (Max + Min)/2; nH = Hill coefficient. When A is an inhibitor, the pA50 is the pIC50.
For 5-HT uptake experiments, the decrease in 5-HT concentration was modelled using a first order kinetic 
model to derive rate constants for 5-HT uptake:
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where: Ct = [5-HT] (µM) at time t (min); t = time from addition of 5-HT (min); C0 = [5-HT] (µM) when t = 0; 
ku = rate constant for 5-HT uptake (min−1). The rate constant represents the probability of 5-HT uptake per unit 
time and is therefore a direct measure of levels of active SERT.
Unless otherwise stated, fitting was performed using minimisation of least squares with the Solver function 
in Microsoft Excel. Data are presented as mean ± standard error (SE) unless otherwise stated. ANOVAs were 
performed using the UNIANOVA procedure in IBM SPSS (v23). Figures were generated using R (v3.3.2) (The R 
Foundation for Statistical Computing, Vienna, Austria).
Densitometry data were fitted to the 4PL model, with additional parameters incorporated to model basal lev-
els of phosphorylation (i.e., no agonist) and background (no protein). Non-linear mixed effects modelling (densi-
tometry and 5-HT uptake data) was performed using NONMEM 7.3 (Icon PLC, Dublin). The objective function 
used by NONMEM 7.3 was extended least squares, and is determined using maximum likelihood estimation64. 
NONMEM allows data from all experiments to be analysed simultaneously and random variation between exper-
iments to be incorporated and quantified. This eliminates the requirement for data normalisation, generates more 
precise population parameter estimates, and allows specific hypothesis tests to be performed between alternative 
models using likelihood ratio tests (LRT)65.
Data availability statement. The datasets generated and analysed during the current study are available 
on request.
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